Critical Collaborators
This article was originally published in RPM Report
Executive Summary
The Food & Drug Administration's dream of identifying a "critical path" to improve drug development productivity is one step closer to moving from rhetoric to reality. Three months after the official blessing from the Department of Health & Human Services for an effort by the C-Path Institute (in Tucson, Arizona) to create a consortium to validate preclinical toxicity test methods, C-Path has signed on nearly a dozen willing participants from big pharma.
You may also be interested in...
Good Predictions: FDA Encouraged by Biomarker Progress
It's been just over a year since the Food & Drug Administration started down the Critical Path to drug development reform, and senior agency staffers are already exuding confidence that at least one of its first showcase projects will be a winner.
Good Predictions: FDA Encouraged by Biomarker Progress
It's been just over a year since the Food & Drug Administration started down the Critical Path to drug development reform, and senior agency staffers are already exuding confidence that at least one of its first showcase projects will be a winner.
FDA Leadership Changes Reflect Budgetary, Scientific Challenges
FDA has a new chief operating officer and medical officer. The appointments reflect the challenges of a lean budget and calls for a chief scientist from the Institute of Medicine.